CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 501 enrolled
Drug / intervention
insulin degludec +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02034513
NCT02034513Phase 3Completed
CompareCT.gov

A Randomised, Double Blind, Cross-over Trial Comparing the Safety and Efficacy of Insulin Degludec and Insulin Glargine, Both With Insulin Aspart as Mealtime Insulin in Subjects With Type 1 Diabetes (SWITCH 1)

Novo Nordisk A/S·interventional·Posted Jan 13, 2014·Updated Jan 2, 2019

In Brief

A Phase 3 clinical trial evaluating insulin degludec, insulin glargine, and 1 other intervention for Diabetes and Diabetes Mellitus, Type 1. Completed, enrolled 501 participants across 99 sites in 3 countries.

Detailed Summary

This trial is conducted in Europe and the United States of America (USA). The aim of the trial is to compare the safety and efficacy of insulin degludec (IDeg) and insulin glargine (IGlar), both with insulin aspart (IAsp) as mealtime insulin in subjects with type 1 diabetes.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes, Diabetes Mellitus, Type 1
CountriesPoland, Puerto Rico, United States
Collaborators--

Timeline

Phase 3CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedJan 13, 2014
Enrollment StartJan 5, 2014
Primary CompletionJan 11, 2016
TodayJul 2, 2026
Enrollment to primary: 2.0 yearsPosted 12.5 years ago

Interventions

insulin degludecdrug

Administered once daily, injected s.c. / subcutaneously (under the skin). Dose is individually adjusted.

insulin glarginedrug

Administered once daily, injected s.c. / subcutaneously (under the skin). Dose is individually adjusted.

insulin aspartdrug

Administered 2-4 times daily injected s.c. / subcutaneously (under the skin). Dose is individually adjusted.